Literature DB >> 27907914

Anxiety and Coping Strategy Changes in Multiple Sclerosis Patients Initiating Fingolimod: The GRACE Prospective Study.

Thibault Moreau1, Catherine Bungener, Olivier Heinzlef, Laurent Suchet, Florent Borgel, Isabelle Bourdeix, Mohamed Meite, Karin Rerat, Isabelle Chouette.   

Abstract

The objective of this prospective study was to assess the changes in anxiety levels, and their relationship with coping strategies over the first four months of fingolimod treatment in patients with relapsing remitting multiple sclerosis (RRMS). Data were collected at the inclusion visit (Visit 1) and 4 months later (Visit 2). We used the Hospital Anxiety and Depression Scale (HADS) to assess the level of anxiety and the Coping Inventory for Stressful Situations scale to assess the coping strategies used when engaged with stressful situations. The HADS anxiety scores were compared between Visits 1 and 2, according to the preferred coping strategy. At Visit 1, half of the 198 patients included were considered to be anxious (doubtful or in a certain way). The same proportion preferentially used an avoidance-oriented strategy and one-third preferentially used an emotion-oriented strategy. The mean HADS anxiety score decreased significantly (p = 0.001) at Visit 2 (8.1 ± 4.0) compared to Visit 1 (8.8 ± 4.3), particularly in the group of patients who used an emotion-oriented strategy (p = 0.002). In conclusion, the initiation of fingolimod in patients with RRMS is followed by a decrease of anxiety levels which vary according to the coping strategy used.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27907914     DOI: 10.1159/000451077

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  4 in total

1.  Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study.

Authors:  Caroline Papeix; Giovanni Castelnovo; Emmanuelle Leray; Marc Coustans; Pierre Levy; Jean-Marc Visy; Gisela Kobelt; Fabienne Lamy; Bashar Allaf; François Heintzmann; Isabelle Chouette; Eric Raponi; Barbara Durand; Emmanuelle Grevat; Driss Kamar; Marc Debouverie; Christine Lebrun-Frenay
Journal:  Neurol Ther       Date:  2022-02-11

2.  Importin α5 Regulates Anxiety through MeCP2 and Sphingosine Kinase 1.

Authors:  Nicolas Panayotis; Anton Sheinin; Shachar Y Dagan; Michael M Tsoory; Franziska Rother; Mayur Vadhvani; Anna Meshcheriakova; Sandip Koley; Letizia Marvaldi; Didi-Andreas Song; Eitan Reuveny; Britta J Eickholt; Enno Hartmann; Michael Bader; Izhak Michaelevski; Mike Fainzilber
Journal:  Cell Rep       Date:  2018-12-11       Impact factor: 9.423

Review 3.  Sphingolipids as prognostic biomarkers of neurodegeneration, neuroinflammation, and psychiatric diseases and their emerging role in lipidomic investigation methods.

Authors:  Daan van Kruining; Qian Luo; Gerhild van Echten-Deckert; Michelle M Mielke; Andrew Bowman; Shane Ellis; Tiago Gil Oliveira; Pilar Martinez-Martinez
Journal:  Adv Drug Deliv Rev       Date:  2020-04-28       Impact factor: 15.470

Review 4.  Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.

Authors:  Kerri A Schoedel; Carine Kolly; Anne Gardin; Srikanth Neelakantham; Kasra Shakeri-Nejad
Journal:  Psychopharmacology (Berl)       Date:  2021-11-13       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.